Analysis of diagnosis and treatment status of pseudomyxoma peritonei based on real-world data
Ying Zhang,Xinbao Li,Yulin Lin,Ru Ma,Dazhao Xu,Xin Zhao,Fengcai Yan,Yan Li
DOI: https://doi.org/10.12354/j.issn.1000-8179.2022.20211037
2022-01-01
Chinese Journal of Clinical Oncology
Abstract:Abstract Objective To analyze the diagnosis and treatment status, natural course, and related factors of patients with pseudomyxoma peritonei based on Chinese real-world data. Methods Retrospective analysis was conducted on real world data of PMP patients with a complete natural history at the our center from February 2009 to July 2020, including clinicopathological characteristics, non-standardized treatment (time of misdiagnosis, time of mistreatment, previous anti-tumor treatment), CRS + HIPEC treatment (operation time, intraoperative blood transfusion, PCI score, CC score, number of organ removed, number of peritoneal resection areas, serious adverse events (SAE)), and the end point of follow-up was death due to disease-specific death. The natural course and the postoperative course of disease and related factors were analyzed. Results a total of 142 patients were included, 83 (58.5%) males and 59 (41.5%) females, the median age was 55 (24~79) years old, the median time of misdiagnosis was 0.8 (0~62.5) months, and the median time of mistreatment was 15.6 (0~411.1) months. The median time of misdiagnosis and mistreatment after 2016 was shorter than that before. All patients were treated with CRS + HIPEC. The median operation time was 10 (3.33~16.5) h, and the median PCI score was 33 (3~39). The median overall survival of the natural course was 30.3 (2.4~416.7) months, and the 1 -, 2 -, 3-and 5-year survival rates were 90.1%, 62.7%, 43.7% and 19.7%, respectively. Multivariate analysis showed that there were three independent prognostic factors affecting the natural course: PSS 1–3 (HR = 0.472, 95%CI:0.324 ~ 0.688, P = 0.000), lymph node metastasis (HR = 2.219, 95%CI:1.226 ~ 4.014, P = 0.008), and number of CRS + HIPEC operations (HR = 0.523, 95%CI:0.353 ~ 0.777, P = 0.001). Median postoperative survival was 11.93 (0.03~79.70) months, and the 1 -, 2 -, 3-and 5-year postoperative survival rates were 49.3%, 19.7%, 10.6% and 1.4%, respectively. Multivariate analysis showed that there were five independent prognostic factors affecting the postoperative course: previous targeted therapy (HR = 1.628, 95%CI:1.017 ~ 2.607, P = 0.042), occurrence of serious adverse events (SAE) (HR = 1.562, 95%CI:1.053 ~ 2.317, P = 0.026), preoperative CEA level > 39.29 ng/mL (HR = 0.667, 95%CI:0.462 ~ 0.963, P = 0.031), postoperative adjuvant therapy (HR = 0.418, 95%CI:0.284 ~ 0.614, P = 0.000). Postoperative SAE occurred in 44 cases (31%), and 4 cases (2.8%) died within 30 days after operation. Preoperative thrombosis and previous intravenous chemotherapy are independent influencing factors of SAE. Conclusion The diagnosis and treatment of PMP in China has a trend of improvement year by year, and CRS + HIPEC is still the standard treatment for PMP. Early diagnosis and the popularization and application of CRS + HIPEC procedures still need to be strengthened. How to reduce postoperative complications is still a problem that we need to solve.